A speech pathology practice in Australia is typically worth between 2x and 5x its annual EBITDA. A solo practice generating $120,000 in owner earnings will generally sell for $240,000–$360,000. A multi-clinician practice generating $400,000 EBITDA, with NDIS registration and solid associate tenure, can achieve $1.4 million to $2 million. The gap between those two outcomes isn’t random — it comes down to owner dependency, revenue quality, and whether a buyer can actually run the thing without you.
If you’re thinking about selling, here’s how the numbers actually work.
What Drives a Speech Pathology Practice Valuation
The core of any practice valuation is earnings — specifically, what the business generates after paying clinicians, rent, admin staff, and every other cost except your own salary. That figure (EBITDA, or earnings before interest, tax, depreciation, and amortisation) is then multiplied by a factor that reflects how reliable those earnings are and how easily a new owner could maintain them.
For speech pathology practices in Australia, the multiple ranges from about 2x to 5x. Where you land depends on five things.
1. Solo or multi-clinician? A solo practice is, fundamentally, a job. When you stop working, revenue stops. Buyers price that risk heavily — expect 1.5x to 2.5x earnings if you’re the only fee earner. A practice with three or more associate clinicians, where you’re running the business rather than filling the caseload, changes the profile entirely. Those businesses sell for 3x to 5x EBITDA because revenue doesn’t evaporate when you hand over the keys.
2. NDIS registration. If your practice is NDIS-registered and holds a meaningful participant roster — say, 80 to 200 active NDIS clients receiving regular services — that’s recurring, government-backed revenue. Buyers love it. NDIS-registered practices with a stable participant base attract the upper end of the range. Practices relying entirely on Medicare CD items or private pay are more exposed to referral fluctuations and attract lower multiples. (The NDIS price guide caps your rate, but it also creates revenue certainty that private markets don’t.)
3. Revenue source mix. A practice with revenue spread across NDIS, Medicare, private pay, and school contracts is structurally more defensible than one that’s 90% reliant on a single stream. Buyers — particularly platform operators looking at multiple acquisitions — will discount for concentration risk.
4. Staff stability. Speech pathologists are in genuine shortage in Australia. The Australian Government’s skilled occupation list isn’t just bureaucratic trivia — it means that a buyer acquiring your practice has to staff it in a competitive labour market. If your associates have been with you for three or more years, that’s a material asset. If you’ve had three new graduates cycle through in as many years, expect a buyer to price in recruitment and training risk.
5. Referral source quality. Who sends you clients? A practice with deep relationships with paediatricians, GP networks, and schools in a defined geographic area has defensible referral flow. A practice where 60% of clients came via Google and could just as easily go somewhere else is more fragile than the revenue numbers suggest.
The NDIS Factor — and the Risk It Brings
There’s a version of this conversation where NDIS makes your practice look incredibly attractive. And there’s a version where it makes buyers nervous. Both are real, and the difference matters.
The upside: NDIS funding for speech pathology has expanded significantly alongside rising autism and developmental delay diagnoses in Australia. Paediatric speech pathology practices with established NDIS participant rosters are in genuine demand from acquirers — national allied health platforms, private equity-backed operators, and individual clinicians looking to step into ownership.
The risk: the NDIS price guide constrains your revenue ceiling. When the NDIA freezes or reduces support rates, you absorb it. And the 2024-25 NDIS reforms introduced real uncertainty around plan management and unregistered providers. Buyers scrutinise NDIS revenue carefully — particularly whether your registered service agreements are current, your NDIS compliance documentation is clean, and your participant base is stable or growing.
A practice generating $350,000 EBITDA with 80% NDIS revenue and clean compliance history is a fundamentally different asset from one with the same EBITDA but lapsed participant agreements and a compliance audit pending. (One of those I’ve seen close at $1.6M. The other didn’t close at all.)
How Much Is a Solo Speech Pathology Practice Worth?
Bluntly: less than you’d like, and probably more than you’d get if you just locked the door tomorrow.
A solo practice billing $400,000–$600,000 annually, where the principal performs most of the clinical work, typically generates $100,000–$180,000 in owner earnings. Apply a multiple of 1.5x to 2.5x, and you’re looking at a sale price of $150,000–$450,000. The practice has value — the patient base, the referral relationships, the brand, the AHPRA registration, and the lease all have worth — but buyers understand that without a transition period and sometimes an earn-out, much of that goodwill walks out the door with you.
If you’re a solo principal thinking about selling, the single most value-creating thing you can do is hire an associate clinician 12 to 24 months before you go to market. That single step shifts the valuation methodology from “what’s your goodwill worth” to “what’s a sustainable business worth” — and the gap between those two is significant.
What a Multi-Clinician Practice Can Achieve
A practice with four or five associate clinicians, a practice manager, clean systems, and genuine NDIS registration in a metro or regional Australian location can attract serious buyers at multiples you won’t see in most small business categories.
Here’s a rough benchmark: a Perth paediatric speech pathology practice with five clinicians, $600,000 EBITDA, 60% NDIS revenue, and a practice manager running the day-to-day sold in 2024 at approximately 4.2x EBITDA. The owner had built systems that didn’t require their clinical presence. The referral network was institutionalised rather than personal. The buyer — a national allied health group — was prepared to pay for that structural quality.
The same numbers without the systems — where the founder was still seeing 30 clients per week and every referral came through their personal network — would have sold for half as much.
Valuation Methods Buyers Use
Most buyers apply one or both of these approaches as a cross-check.
Capitalised earnings. The most common method. Calculate your normalised EBITDA (see below for what that means), apply a multiple, and that’s your baseline. For smaller practices, a buyer might use owner earnings (profit before your own salary and super) rather than EBITDA — same concept, slightly different inputs.
Asset value. Less common for a going-concern practice, but relevant for practices in wind-down or where earnings have been inconsistent. This values the equipment, software, patient database, and lease separately. Usually produces a lower number than earnings-based methods.
Revenue multiple. Sometimes used as a rough sanity check. Allied health practices in Australia occasionally change hands at 0.7x to 1.2x annual revenue, though this method ignores profitability and isn’t reliable as a standalone approach.
The normalised EBITDA is worth explaining. Buyers will adjust your reported profit to remove:
- Your own salary at market rate (if you’re working in the business, your labour has a cost)
- Personal expenses run through the business (the car, the phone, the conference trip to Bali that was technically CPD)
- One-off costs that won’t recur under new ownership
- One-off revenue bumps that won’t repeat
What’s left is what the business actually earns on a sustainable basis — and that’s what gets multiplied.
What Buyers Are Looking For Right Now
The market for allied health practices in Australia in 2025 and 2026 is active, with national platform operators actively acquiring in metro and regional locations. Speech pathology specifically benefits from structural tailwinds: the NDIS is expanding, paediatric diagnostic rates are increasing, and there are not enough registered clinicians to go around.
Buyers prioritising acquisitions right now include:
- National allied health groups (Kids First, Ability Action Australia, and similar)
- Private equity-backed healthcare platforms
- Individual clinicians stepping into ownership with bank debt
Each category values your business slightly differently. A PE-backed platform is modelling a buy-and-integrate thesis and will pay more for scale and clean systems. An individual clinician buying their first practice is more sensitive to price and more reliant on owner financing. Understanding which buyer type your practice is likely to attract shapes how you position it.
If your practice is a good fit for a platform acquisition, a competitive process run by an advisor can meaningfully shift your sale price. I’ve seen the difference between a negotiated sale and a properly run process be 30–40% of enterprise value — which at a $1.5M practice is real money.
Before You Go to Market
If you’re two or more years from selling, the most impactful things to do are: build a clinical team that doesn’t depend on your presence, formalise your NDIS documentation and participant agreements, and establish systems for client intake and practice management that a new owner could operate from day one.
If you’re closer to selling, focus on financial records. Three years of clean P&Ls, a list of your NDIS participants with service agreement status, and documentation of your referral sources are the minimum a buyer’s due diligence will require. The more you’ve prepared, the faster the process moves — and the less leverage a buyer has to renegotiate on price mid-deal.
For a sense of what your practice might be worth right now, you can use our valuation calculator for a quick benchmark, or get in touch if you’d like to talk through the numbers with someone who knows the allied health market.
Frequently Asked Questions
How much is my speech pathology practice worth in Australia? Most Australian speech pathology practices sell for 2x to 5x EBITDA. A solo practice with $120,000 owner earnings typically achieves $240,000–$360,000. A multi-clinician practice generating $400,000 EBITDA with NDIS registration can sell for $1.4M–$2M. The multiple depends on owner dependency, revenue quality, and staff stability.
What is EBITDA for a speech pathology practice? EBITDA is your practice profit before interest, tax, depreciation, and amortisation — but also before your own salary. It represents what the business earns as a standalone entity. For valuation, buyers adjust it further to remove personal expenses and one-off items, leaving “normalised EBITDA” as the basis for applying a multiple.
Does NDIS registration increase my practice value? Yes, materially. NDIS registration with a stable participant roster — clean compliance history, current service agreements — attracts buyers and supports higher valuation multiples. Government-backed recurring revenue is structurally more attractive than private-pay referral income. A lapsed or troubled compliance history has the opposite effect.
How long does it take to sell a speech pathology practice in Australia? Typically six to twelve months from engagement to settlement. Practices with clean financials, a clinical team in place, and NDIS documentation in order tend to close faster. Solo practices with owner-dependent revenue take longer to market and sometimes require a transition earn-out structure, which extends the overall timeline.
Should I use a broker or a corporate advisor to sell my practice? For practices worth under $400,000, a healthcare business broker may be adequate. For practices worth $500,000 and above — particularly those with NDIS complexity or the potential for a competitive multi-buyer process — a corporate advisory firm with allied health experience will typically generate better outcomes. The difference is in how the process is run and who’s sitting across the table from you.
For related reading on how general healthcare businesses are valued in Australia, or how NDIS businesses are bought and sold, those articles cover the broader framework. EBITDA multiples by industry gives you the wider Allied Health benchmarks.